Physician profile
Anthony Joseph Vannorman
NPI 1538297791
$18,669.39
in general payments reported to CMS, 2019-2025
44 companies · $3,804 in 2025
The $3,804 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,920 · 2020: $606 · 2021: $1,292 · 2022: $2,819 · 2023: $3,984 · 2024: $4,245 · 2025: $3,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,767.22 |
| Education | $265.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,275.74 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $2,425.21 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $1,357.88 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $1,307.57 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $1,281.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,000.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $953.31 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $822.76 | 2019-2025 | Adbry, Spevigo, Anzupgo |
| Pfizer INC. | $813.77 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $597.31 | 2019-2025 | Dupixent |
| Biofrontera INC. | $594.74 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $566.09 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $536.94 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $474.37 | 2019-2025 | Nemluvio, Aklief |
| Prugen, INC. Pharmaceuticals | $448.97 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $278.90 | 2019-2024 | Winlevi |
| Journey Medical Corporation | $268.89 | 2019-2025 | |
| Organogenesis INC. | $245.71 | 2023-2025 | Puraply, Affinity, Puraply Wound Matrix |
| Dermavant Sciences, INC. | $238.48 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.48 | 2022-2025 | Spevigo, Cyltezo |
| Celgene Corporation | $178.10 | 2019 | |
| Mayne Pharma Commercial LLC | $104.20 | 2023-2025 | |
| Vyne Pharmaceuticals INC. | $98.23 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.61 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Fresenius Kabi USA, LLC | $74.93 | 2023-2024 | Idacio |
| Biocon Biologics INC | $68.82 | 2024-2025 | Yesintek, Hulio |
| Dermira, INC. | $53.63 | 2019 | |
| Mission Pharmacal Company | $33.33 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $29.78 | 2023-2025 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $26.98 | 2022-2023 | Valchlor |
| Aclaris Therapeutics, INC. | $24.90 | 2019 | |
| Tactile Systems Technology INC | $22.14 | 2023 | Flexitouch Plus, Entre Plus |
| Kerecis Limited | $21.71 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Kyowa Kirin, INC. | $19.98 | 2019 | |
| Bioventus LLC | $19.15 | 2022 | |
| Polynovo North America LLC | $17.57 | 2022 | |
| Organon LLC | $15.64 | 2025 | Vtama |
| Promius Pharma LLC | $15.61 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.34 | 2025 | Zoryve |
| Nabriva Therapeutics, Plc | $14.69 | 2021 | |
| Encore Dermatology INC. | $12.68 | 2020 | |
| Almirall LLC | $12.16 | 2019 | |
| Strata Skin Sciences, INC. | $12.06 | 2022 | |
| Genentech USA, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Vannorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.